Rise Therapeutics
Private Company
Total funding raised: $30M
Overview
Rise Therapeutics is a private, clinical-stage biotech developing first-in-class oral immunotherapies for autoimmune diseases and cancer. Its core innovation is a proprietary oral drug delivery platform that enables the targeted delivery of biologic therapies, a significant advancement over traditional injectable biologics. The company has built integrated capabilities from discovery through in-house GMP manufacturing, accelerating multiple programs into clinical trials. With four active clinical programs and recent funding, Rise is positioned to validate its platform and address major unmet needs in immunology.
Technology Platform
Proprietary synthetic biology-based oral drug delivery platform enabling targeted oral administration of biologic therapies (Oral Immune BioModulators) designed to reprogram immune cells, specifically dendritic cells.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Rise competes with major pharmaceutical companies developing both injectable biologics and oral small molecules for autoimmunity and cancer. Its direct competitors are other biotechs working on oral biologic delivery or novel immune modulators. Its key differentiator is the combination of oral delivery with targeted dendritic cell programming, a niche with few, if any, clinical-stage analogues.